Targeting important molecular ‘hubs’ where the Hippo, Notch and DDR pathways converge, such as the AR, ERG, AKT and TLK/NEK, may yield productive therapeutic approaches in prostate cancer. Here, AKT1 is linked to prostate carcinoma.